There are currently 82 clinical trials in Columbus, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including John B. Amos Cancer Center, Columbus Regional Research Institute, GSK Investigational Site and IACT Health. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Teplizumab in Pediatric Stage 2 Type 1 Diabetes
NCT05757713
Recruiting
The purpose of this study is to assess the safety and pharmacokinetics (PK) of teplizumab in participants with Stage 2 type 1 diabetes who are <8 years of age.
Gender:
All
Ages:
Between 0 years and 7 years
Trial Updated:
04/12/2024
Locations: Clinical Site 104, Columbus, Georgia
Conditions: Diabetes Mellitus, Type 1
Register for Updates
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
NCT03418961
Recruiting
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: John B Amos Cancer Center, Columbus, Georgia
Conditions: Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Register for Updates
Deep Neural Network Stratification for Use Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck)
NCT05245695
Recruiting
The goal of this observational study is to determine the clinical validity of a deep neural network algorithm that utilizes protein biomarker detection of Endometriosis - "EndoCheck" - as an "aid in diagnosis" for endometriosis and to show validity as a diagnostic test
Gender:
Female
Ages:
Between 14 years and 50 years
Trial Updated:
02/15/2024
Locations: Midtown OBGYN North, Columbus, Georgia
Conditions: Endometriosis
Register for Updates
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.
NCT05763121
Recruiting
This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma with an eosinophilic phenotype and a history of asthma exacerbations.
Gender:
All
Ages:
Between 12 years and 99 years
Trial Updated:
02/09/2024
Locations: Research Site 20001-018, Columbus, Georgia
Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Register for Updates
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
NCT05748600
Recruiting
The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma to evaluate improvements in lung function, asthma control, and quality of life. In addition, the study will further evaluate the safety and tolerability of dexpramipexole in participants with eosinophilic asthma.
Gender:
All
Ages:
Between 12 years and 99 years
Trial Updated:
02/09/2024
Locations: Research Site 40001-018, Columbus, Georgia
Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack
Register for Updates
Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout
NCT05818085
Recruiting
This is a multicenter, randomized, double-blind, Phase 2b/3 study to evaluate the efficacy and safety of ABP-671. Part 1 of the study will compare the efficacy and safety of different doses and regimens of ABP-671 with placebo and allopurinol. Part 2 of the study will compare the dosing regimen(s) of ABP-671 selected from Part 1 with placebo in participants who have not been enrolled for Part 1.
Gender:
All
Ages:
Between 19 years and 69 years
Trial Updated:
02/08/2024
Locations: Centricity Research, Columbus, Georgia
Conditions: Gout
Register for Updates
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
NCT04468659
Recruiting
The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with lecanemab is superior to placebo in reducing brain amyloid accumulation as measured by amyloid positron emission tomography (PET) at 216 weeks of treatment (A3 Trial). This study will also evaluate the long-term safety and tolerabili... Read More
Gender:
All
Ages:
Between 55 years and 80 years
Trial Updated:
02/06/2024
Locations: Columbus Memory Center, PC, Columbus, Georgia
Conditions: Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
Register for Updates
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
NCT03093116
Recruiting
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blin... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
02/05/2024
Locations: Colombus Regional Research Institute, Columbus, Georgia
Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors
Register for Updates
A Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS)
NCT05895552
Recruiting
This is a 2-part, randomized, placebo-controlled, double-blind, Phase 2 study to evaluate the safety, tolerability, efficacy, and PK of RTA 901 in qualified subjects with DPNP. Each study part will be randomized into 3 treatment arms; 2 different doses of RTA 901 and a Placebo. The doses of RTA 901 in Part 2 will be selected based on the Exposure-Response (E-R) analyses of data from Part 1. A total of 384 subjects will be randomized in this study. Each part will have 192 subjects, with 64 subjec... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/31/2024
Locations: Centricity Research Columbus Endocrinology, Columbus, Georgia
Conditions: Diabetic Peripheral Neuropathic Pain
Register for Updates
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: IACT Health, Columbus, Georgia
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
Prospective Multi-Center Trial for FemBloc Permanent Birth Control
NCT05977751
Recruiting
Prospective, multi-center, international, unblinded, single-arm trial of subjects undergoing FemBloc followed by ultrasound confirmation test.
Gender:
Female
Ages:
Between 21 years and 50 years
Trial Updated:
01/22/2024
Locations: Midtown OB GYN North, Columbus, Georgia
Conditions: Contraception
Register for Updates
A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer
NCT05930210
Recruiting
This Phase 3 study is a randomized, double-blind, vehicle-controlled, multiple-center, parallel study to evaluate efficacy and safety of ENERGI-F703 GEL compared with vehicle control in subjects with Wagner Grade 1 to Grade 2 diabetic foot ulcers. Baseline target ulcer size (<16 cm2 vs ≥16 cm2 ) will be included as a stratification factor. Subjects will be randomized 1:1 to receive ENERGI-F703 GEL or vehicle control using an interactive web response system for randomization to automatically assi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/21/2023
Locations: IACT Health, Columbus, Georgia
Conditions: Diabetic Foot Ulcer, Foot Ulcer, Diabetes Mellitus, Wound
Register for Updates